Moteur de recherche d’entreprises européennes
Financement de l’UE (5 965 968 €) : Surdosage de gènes et comorbidités au début de la vie dans le syndrome de Down Hor26/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Surdosage de gènes et comorbidités au début de la vie dans le syndrome de Down
The aim of the project is to elucidate etiological mechanisms involved in the appearance of obesity, and intellectual disability comorbidities in Down syndrome (DS). With its incidence of 1 in 1000 births, DS offers a great opportunity to uncover common/novel mechanisms because it is associated with a higher risk to develop several obesity, and intellectual disability. The increased risk to develop this combination of comorbidities in DS, suggests that specific genetic or epigenetic mechanisms associated with trisomy 21 (the cause of DS) predispose to this comorbidity. For this aim, GO-DS21 will have the following objectives: 1) To determine age-related comorbidity patterns observed over the early lifetime (before age 45) in persons with Down syndrome (WP1). 2) To identify specific physiological biomarkers (WP4), and regulatory and epigenetic signatures (WP5) in human, cellular and animal models. 3) To decipher the contribution of environmental factors (stress, diet, exercise) to trisomy 21 obesity/ID comorbidities in preclinical models (WP2, 3). 4) To investigate the effects of overdosage of three Hsa21 candidate genes (DYRK1A, MRAP, NRIP1) to explain comorbid patterns in mouse models (WP3). 5) To integrate multilevel data from human patients, preclinical and cellular models across different spatial and temporal scales of biological complexity using computational biology models and machine learning approaches (WP6). 6) To design new therapeutic interventions to reduce the penetrance of comorbidities in preclinical models (WP3 and WP4). This approach will help to improve diagnosis and understanding of prognostic factors, and will establish recommendations and targeted interventions to prevent or minimise comorbidities in persons with DS (WP7). Beyond the impact for patients with DS we expect that findings of this project will also be beneficial for patients in the general population.
| CONCENTRIS RESEARCH MANAGEMENT GmbH | 370 000 € |
| Centre Europeen de Recherche en Biologie et Medecine | 1 029 185 € |
| 554 556 € | |
| Fundacio Institut Hospital del Mar D Investigacions Mediques | 391 744 € |
| HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM für GESUNDHEIT UND UMWELT GmbH | 928 025 € |
| Institut Jerome Lejeune | 344 044 € |
| Institut du Cerveau et de la Moelle Epiniere | 540 000 € |
| King's College London | 567 999 € |
| Perha Pharmaceuticals SAS | 200 000 € |
| Queen Mary University of London | 579 885 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 440 530 € |
| 20 000 € |
https://cordis.europa.eu/project/id/848077
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "CONCENTRIS RESEARCH MANAGEMENT GmbH - Financement de l’UE (5 965 968 €) : Surdosage de gènes et comorbidités au début de la vie dans le syndrome de Down"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
